Gorlice

• A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious … Recruiting
  2025-522347-18-00 4 2025-11-26 Major Depressive Disorder (MDD), with or without Anxious Distress
• A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting
  2024-513302-56-00 4 2025-11-17 Generalized Anxiety Disorder
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi … Recruiting
  2023-509070-36-00 5 2025-03-18 Major Depressive Disorder with Insomnia Symptoms
• MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting
  2023-507776-42-00 5 2024-11-14 Non-small cell lung cancer
• Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting
  2023-510128-66-00 5 2024-09-02 Participants with treatment-naïve metastatic squamous Non-small Cell L
• An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended
  2023-506570-12-01 4 2024-06-13 Cognitive disorder

Showing 1–7 of 7 trials